This ALT assay path starts with alanine aminotransferase making pyruvate, then lactate dehydrogenase converts that pyruvate to lactate while NADH becomes NAD+. The observable signal is the drop in NADH at 340 nm, tying enzyme activity to the lactate/NAD+ pair and making the readout a straightforward measure of ALT activity.

Multiple Choice

In the ALT assay using pyruvate, what is the reaction product?

Alanine aminotransferase catalyzes a transamination that produces pyruvate from alanine (with α-ketoglutarate accepting the amino group to form glutamate). In the common clinical ALT assay, that pyruvate is then immediately acted on by lactate dehydrogenase, using NADH to reduce pyruvate to lactate. This coupled step converts NADH to NAD+, so the observable products of the overall assay are lactate and NAD+. That is why the reaction product is lactate plus NAD+. The assay readout relies on the decrease in NADH absorbance at 340 nm, reflecting ALT activity.

ALT and the neat little dance of pyruvate

If you’ve ever peeked under the hood of a clinical chemistry analyzer, you’ve likely stumbled upon ALT assays more than once. Alanine aminotransferase, the enzyme that sits at the crossroads of amino acid metabolism and energy production, has a simple enough job on paper: it swaps an amino group from alanine onto α-ketoglutarate, making pyruvate and glutamate. But then the plot thickens with a second enzyme coming into the scene. That second actor is lactate dehydrogenase, and it uses NADH as a partner in crime (or, more politely, as a cofactor) to transform pyruvate into lactate. The clever twist? Every time NADH donates electrons, it becomes NAD+. And that little molecular change—NADH to NAD+—is what the assay actually watches.

Let me explain the chemistry in a friendly, step-by-step way.

Two enzymes, one clean readout

Think of ALT as the starter pistol. It takes alanine and α-ketoglutarate and performs a transamination: the amino group hops from alanine to α-ketoglutarate. The immediate products are pyruvate and glutamate. At first glance, you might expect this pyruvate to be the end of the line. But in the clinical assay world, pyruvate is just the opening act.

Enter lactate dehydrogenase (LDH), the second enzyme in the usual ALT assay setup. LDH recognizes pyruvate and NADH as its substrate pair. It reduces pyruvate to lactate, and in the process, NADH loses a pair of electrons and becomes NAD+. The chemical transformation is tidy, and it’s precisely what the instrument is built to track: the consumption of NADH.

From a readout standpoint, this means the assay’s signal is a decrease in NADH absorbance at 340 nm. NADH absorbs light at this wavelength, NAD+ does not. So, as the reaction proceeds, the NADH concentration falls, the absorbance drops, and the instrument converts that into a numeric readout that clinicians rely on to gauge ALT activity.

What’s the observable product, really?

If you’re answering a multiple-choice item, the summary is simple: the overall reaction, as commonly implemented in ALT assays, ends up with lactate and NAD+ as the observable products. You might see the question framed as “what is the reaction product?” and the tempting trap is to pin it on pyruvate or some intermediate. In the standard, coupled ALT-LDH assay, the “end products” you monitor are lactate and NAD+, not simply pyruvate. The lactate is the crystal-clear endpoint of the second reaction, and NAD+ is the stoichiometric partner created by the reduction of NADH.

A quick detour into why this setup is used

Why couple ALT with LDH in the first place? It boils down to a matter of a clean, continuous readout. ALT’s catalytic step produces pyruvate, which isn’t as easy to measure directly in many clinical settings. Pyruvate does have a signal, but the enzyme–cofactor chemistry that follows is less predictable in a busy clinical analyzer. LDH provides a robust, continuous signal—NADH’s absorbance at 340 nm changes predictably as pyruvate becomes lactate. This makes the assay fast, reproducible, and compatible with standard spectrophotometers.

It’s also a nice example of how biochemistry often solves a measurement problem with a clever coupling. In a lab, you rarely measure a single reaction in isolation. You connect steps so that the downstream products yield a clear, quantifiable readout. In this case, turning the pyruvate story into a lactate-and-NAD+ story makes the math and the optics straightforward.

A sidebar on the players: ALT and LDH

Alanine aminotransferase is a relatively modest enzyme in the grand scheme of metabolism, but it’s a workhorse in clinical chemistry. It’s one of those enzymes you watch when the liver’s health is in question. Elevated ALT can signal hepatocellular damage, since liver cells release ALT into the bloodstream when their membranes fray. It’s not a perfect biomarker—no single test is—but it’s a useful piece of the broader diagnostic puzzle.

Lactate dehydrogenase is a different kind of multitasker. It’s everywhere—heart, liver, kidneys, skeletal muscle, red blood cells. Its job is to shuttle electrons in the final step of anaerobic glycolysis, converting pyruvate to lactate when oxygen is scarce or when the cell wants to regenerate NAD+ to keep glycolysis humming. In the ALT assay, LDH’s role is the dependable workhorse that drives the signal home.

Real-world quirks you might notice in practice

  • pH and cofactor conditions matter. The enzyme mix is optimized so ALT and LDH both do their jobs smoothly. If the pH drifts or the cofactors aren’t in the right balance, the readout can wander.

  • Interfering substances. Hemolysis, lipemia, or high bilirubin can muddy spectrophotometric measurements. That’s always something clinical labs watch for, especially when the patient’s samples are a bit unruly.

  • Temperature control. Enzyme activity is temperature-sensitive. Most clinical analyzers run at a fixed temperature, and flags can pop if the sample’s temperature disagrees with the operating setpoint.

Why this matters beyond the digits

For students stepping into clinical chemistry, the ALT-LDH couple is a microcosm of how labs translate biology into numbers we can act on. It’s a reminder that:

  • Enzymes don’t live in isolation on a test tube; they’re part of a choreography designed to yield a stable, interpretable signal.

  • The observable product doesn’t always tell the whole story. In this setup, lactate and NAD+ reflect the net activity, not just a single substrate’s fate.

  • Small design choices—like selecting NADH as the reporter—can unlock a fast, linear readout that fits the workflow of a busy lab.

A few friendly comparisons to keep things grounded

  • If ALT is the starter pistol, LDH is the baton handoff that keeps the relay going. Without the LDH step, you’d be staring at pyruvate, a less friendly readout for a high-throughput analyzer.

  • In the broader world of transaminases, ALT’s partner reactions often feed into central carbon metabolism. Pyruvate sits at a crossroads: it can be shunted toward energy production, gluconeogenesis, or biosynthetic routes. The liver, in particular, loves to juggle these options depending on the body’s needs.

A mental model you can carry into the lab or the classroom

Picture a two-door system. The first door (ALT) passes along a pyruvate note, signaling the front desk that something’s happening with alanine. The second door (LDH) opens and converts that note into lactate and a fresh NAD+. The calendar of the day—your readout—fills with fewer uncertainties because the NADH-to-NAD+ transition is tidy and trackable. That clarity is why these coupled assays endure in routine use.

Common confusions and quick clarifications

  • “Is the product lactate or pyruvate?” In the standard ALT assay, the observed products are lactate and NAD+. Pyruvate is a transient intermediate, not the ultimate readout in this setup.

  • “Do we measure ALT directly?” Not by itself in this configuration. The clean estimate comes from the coupled LDH reaction that consumes NADH, giving a dependable spectroscopic signal.

  • “What about liver disease signals?” ALT elevations can point toward hepatocellular injury, but as with any single test, context matters. Clinicians interpret ALT alongside a constellation of data—clinical picture, other enzymes, imaging, and patient history.

A little narrative on how technology keeps pace

Modern clinical analyzers are marvels of engineering, but their charm lies in the brains behind the scenes. They’re built to handle curves, controls, and calibration with the same calm you’d expect from a well-tuned orchestra. The ALT-LDH duet is a favorite because it’s robust, relatively forgiving of small sample quirks, and gives results fast enough to keep patient care moving. It’s a small symphony in the bigger score of metabolic screening.

If you’re exploring Clinical Chemistry in depth, you’ll find many such coupled reactions, each with its own reasons for existing. Some tests rely on color changes, others on fluorescence or luminescence. The theme is consistent: pair a biochemically meaningful reaction with a measured signal that’s easy to quantify. And if you ever sit with a spectrophotometer, you’ll hear the quiet hum of NADH at 340 nm—a tiny but telling beacon in the chemistry of life.

A concluding thought

The ALT assay using pyruvate isn’t just about ticking a box on a worksheet. It’s a microcosm of how clinicians translate enzyme activity into actionable insights. It shows the beauty of biochemistry in motion: a seamless relay from alanine to pyruvate, then a swift handoff to lactate, with NADH tracing the path like a bright yellow marker you can’t miss. It’s simple in concept, powerful in practice, and a great reminder of how elegantly the body’s chemistry can be measured, understood, and used to guide care. If you remember one thing, let it be this: in many clinical tests, the story you read on the instrument is the sum of clever enzyme teamwork and the constant, dependable signal of NADH changing its state.